Algiax Pharmaceuticals GmbH, an Erkrath, Germany-based developer of an advanced therapy for Neuropathic pain, has raised €4.3m in funding.
Backers include High-Tech Gründerfonds, Private Investors and KfW.
Founded in July 2011 by Dr. Jürgen Schumacher, Managing Director, Algiax Pharmaceuticals is a biotechnology research company dedicated to drug development addressing central nervous system (CNS) illnesses and dysfunctions, with a focus on neuropathic pain.
The substances patented by the company (late preclinical development stage) targets the symptoms of neuropathic pain, also enabling causal therapy of pain induction.
Algiax intends to use the funding to gain approval for the clinical testing stage.
FinSMEs
16/05/2012